JUNS
NASDAQ · Pharmaceuticals
Jupiter Neurosciences Inc
$0.37
-0.01 (-2.87%)
Financial Highlights (FY 2025)
Revenue
4.37M
Net Income
924.0K
Gross Margin
63.0%
Profit Margin
21.1%
Rev Growth
+10.8%
D/E Ratio
0.26
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 63.0% | 63.0% | 63.0% |
| Operating Margin | 28.9% | 30.2% | 30.1% |
| Profit Margin | 21.1% | 23.1% | 24.9% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.37M | 3.89M | 4.34M |
| Gross Profit | 2.75M | 2.45M | 2.74M |
| Operating Income | 1.26M | 1.17M | 1.31M |
| Net Income | 924.0K | 896.5K | 1.08M |
| Gross Margin | 63.0% | 63.0% | 63.0% |
| Operating Margin | 28.9% | 30.2% | 30.1% |
| Profit Margin | 21.1% | 23.1% | 24.9% |
| Rev Growth | +10.8% | +2.3% | +6.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 3.36M | 3.14M | 3.77M |
| Total Equity | 12.95M | 13.36M | 15.30M |
| D/E Ratio | 0.26 | 0.24 | 0.25 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.37M | 1.23M | 1.59M |
| Free Cash Flow | 866.3K | 754.2K | 863.0K |